Panacea Index Logo

Command Palette

Search for a command to run...

The Effect of Intermittent Fasting Diet in Comparison With Low-Calorie Diet on Inflammation, Lipid Profile, Glycemic Index, Liver Fibrosis in Patients With Metabolic-Associated Fatty Liver Disease (MAFLD): A Randomized Controlled Trial.

Clinical therapeutics
April 1, 2025
Mehdi Karimi et al. (9 authors)
Journal ArticleRandomized Controlled TrialComparative StudyHuman StudyClinical
Study Details

Study Goal

The researchers aimed to compare the effects of 16:8 Intermittent Fasting (IF) versus a low-calorie diet (LCD) on metabolic and liver health parameters in patients with metabolic-associated fatty liver disease (MAFLD).

Results Summary

Both 16:8 IF and LCD improved anthropometric measures and liver enzyme levels, but LCD showed superior reductions in liver steatosis, fibrosis, and serum triglycerides. Neither intervention significantly affected inflammatory markers or oxidative status.

Population

52 patients with MAFLD (specific demographics not detailed).

Effective Dosage

16:8 IF (time-restricted feeding window, exact calorie intake not specified).

Duration

10 months.

Interactions

None mentioned.

Extracted Claims (11)
InterventionDirectionEndpointPopulationDosageImpactClaim #
16:8 IF diet
decrease
anthropometric measures
52 patients with MAFLD
-
led to improvements
#1
16:8 IF diet
decrease
liver enzyme levels
52 patients with MAFLD
-
led to improvements
#2
low-calorie diet (LCD)
decrease
anthropometric measures
52 patients with MAFLD
-
led to improvements
#3
low-calorie diet (LCD)
decrease
liver enzyme levels
52 patients with MAFLD
-
led to improvements
#4
low-calorie diet (LCD)
decrease
liver steatosis
52 patients with MAFLD
-52.40 vs -44.63 dB/m
showed superior outcomes in reducing
#5
low-calorie diet (LCD)
decrease
fibrosis
52 patients with MAFLD
-0.74 vs -0.004 Kpa
showed superior outcomes in reducing
#6
low-calorie diet (LCD)
decrease
serum triglycerides
52 patients with MAFLD
-24.08 vs 11.22 mg/dL
led to a significant decrease
#7
16:8 IF diet
no change
inflammatory markers
52 patients with MAFLD
-
neither intervention significantly affected
#8
low-calorie diet (LCD)
no change
inflammatory markers
52 patients with MAFLD
-
neither intervention significantly affected
#9
16:8 IF diet
no change
oxidative status
52 patients with MAFLD
-
neither intervention significantly affected
#10
low-calorie diet (LCD)
no change
oxidative status
52 patients with MAFLD
-
neither intervention significantly affected
#11
Abstract

BACKGROUND: Metabolic-associated fatty liver disease (MAFLD) is a prevalent condition with significant health and economic burdens. Dietary interventions, such as intermittent fasting (IF) and low-calorie diets (LCD), have shown promise in managing MAFLD, but their comparative efficacy remains unclear. METHODS: This 10-month, parallel, single-blind randomized controlled trial compared the effects of a 16:8 IF diet with an LCD on 52 patients with MAFLD. Anthropometric, biochemical, liver enzyme, steatosis, fibrosis, inflammatory, and oxidative status parameters were assessed before and after the interventions. RESULTS: Both diets led to improvements in anthropometric measures and liver enzyme levels, with no significant differences between groups. However, the LCD group showed superior outcomes in reducing liver steatosis (-52.40 vs -44.63 dB/m; P < 0.001) and fibrosis (-0.74 vs -0.004 Kpa; P = 0.01) compared to the IF group. LCD also led to a significant decrease in serum triglycerides (-24.08 vs 11.22 mg/dL; P = 0.02), while neither intervention significantly affected inflammatory markers or oxidative status. CONCLUSION: While both IF and LCD can be effective in managing MAFLD, LCD may offer additional benefits in terms of liver fat reduction and improvement in certain lipid parameters. These findings highlight the complexity of dietary interventions in MAFLD and the need for personalized approaches.

Medical Subject Headings (MeSH)
HumansMaleFemaleCaloric RestrictionFastingMiddle AgedLiver CirrhosisSingle-Blind MethodInflammationAdultLipidsGlycemic IndexNon-alcoholic Fatty Liver DiseaseTreatment OutcomeIntermittent Fasting
Study Links
Quality Scores
SafetyNot Assessed
Efficacy60/10
Quality80/10
Research Impact Scores
APT Score0.05
Weight Score2.60
Normalized Score0.60
Related Supplements